| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Johns Hopkins Oncology Center [D. S., T. T., K. H., B. Z., B. S., L. P., B. V., N. D.], Baltimore, Maryland 21231; Johns Hopkins University, School of Hygiene and Public Health [K. H.], Baltimore, Maryland 21205; and Frederick Memorial Hospital, Regional Cancer Therapy Center [G. R.], Frederick, Maryland 21701
Recent evidence has implicated germ-line mutations of the p53 gene as the cause of cancer susceptibility in the Li-Fraumeni syndrome, associated with the development of breast cancer and other neoplasms. Furthermore, somatic mutations of the p53 gene have been detected in a high percentage of non-familial breast cancers. We therefore sought to identify potential carriers of p53 gene mutations in a cohort of patients with early onset breast cancer. We examined 126 consecutive patients who developed breast cancer at or before the age of 40 for mutations of p53 within conserved regions of the gene. One patient with an inherited germ-line mutation of the p53 gene was identified but the functional significance of this mutation was not clear. It thus appears that only a small percentage of patients with breast cancer under the age of 40 carry germ-line mutations of the p53 gene, an observation which has implications for potential screening and risk assessment in such patients.
1 This work was supported by The Clayton Fund, The McAshan Fund. The Mildred Mindell Foundation, and NIH Grants CA43460 and CA49634.
Received 1/30/92. Accepted 4/ 1/92.
This article has been cited by other articles:
|
|
 |
|
  J. S. Tront, B. Hoffman, and D. A. Liebermann Gadd45a Suppresses Ras-Driven Mammary Tumorigenesis by Activation of c-Jun NH2-Terminal Kinase and p38 Stress Signaling Resulting in Apoptosis and Senescence. Cancer Res., September 1, 2006; 66(17): 8448 - 8454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Thull and V. G. Vogel Recognition and Management of Hereditary Breast Cancer Syndromes Oncologist, February 1, 2004; 9(1): 13 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Pichert, B. Bolliger, K. Buser, and O. Pagani Evidence-based management options for women at increased breast/ovarian cancer risk Ann. Onc., January 1, 2003; 14(1): 9 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D G R Evans and F Lalloo Risk assessment and management of high risk familial breast cancer J. Med. Genet., December 1, 2002; 39(12): 865 - 871. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D G R Evans, J M Birch, M Thorneycroft, G McGown, F Lalloo, and J M Varley Low rate of TP53 germline mutations in breast cancer/sarcoma families not fulfilling classical criteria for Li-Fraumeni syndrome J. Med. Genet., December 1, 2002; 39(12): 941 - 944. [Full Text] [PDF]
|
|
|
|
|
|
M M de Jong, I M Nolte, G J te Meerman, W T A van der Graaf, J C Oosterwijk, J H Kleibeuker, M Schaapveld, and E G E de Vries Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility J. Med. Genet., April 1, 2002; 39(4): 225 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. Nichols, D. Malkin, J. E. Garber, J. F. Fraumeni Jr., and F. P. Li Germ-line p53 Mutations Predispose to a Wide Spectrum of Early-onset Cancers Cancer Epidemiol. Biomarkers Prev., February 1, 2001; 10(2): 83 - 87. [Abstract] [Full Text]
|
|
|
|
|
|
A. CHOMPRET, A. ABEL, D. STOPPA-LYONNET, L. BRUGIÈRES, S. PAGÈS, J. FEUNTEUN, and C. BONAÏTI-PELLIÉ Sensitivity and predictive value of criteria for p53 germline mutation screening J. Med. Genet., January 1, 2001; 38(1): 43 - 47. [Full Text]
|
|
|
|
 |
|
 S. Chaudhuri, A. Cariappa, M. Tang, D. Bell, D. A. Haber, K. J. Isselbacher, D. Finkelstein, D. Forcione, and S. Pillai Genetic susceptibility to breast cancer: HLA DQB*03032 and HLA DRB1*11 may represent protective alleles PNAS, October 10, 2000; 97(21): 11451 - 11454. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J van Orsouw, R. K Dhanda, Y. Elhaji, S. A Narod, F. P Li, C. Eng, and J. Vijg A highly accurate, low cost test for BRCA1 mutations J. Med. Genet., October 1, 1999; 36(10): 747 - 753. [Abstract] [Full Text]
|
|
|
|
 |
|
 V. C. Jordan and M. Morrow Tamoxifen, Raloxifene, and the Prevention of Breast Cancer Endocr. Rev., June 1, 1999; 20(3): 253 - 278. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. A. Sellers Genetic Factors in the Pathogenesis of Breast Cancer: Their Role and Relative Importance J. Nutr., May 1, 1997; 127 (5): 929S - 929S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Robbins p53 and Breast Cancer International Journal of Surgical Pathology, October 1, 1996; 4(2): 93 - 110. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
